SCHEMBL743836

SCHEMBL743836

CN1C2CCC1CC(Oc1ccc(-c3cnc4[nH]ccc4c3)nc1)C2.Cc1ccc(S(=O)(=O)O)cc1

nearest known ligand 0.39

Known targets — ChEMBL curated mechanism

ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PIK3CD known ✓ O00329 2/20 0.38
FLT3 known ✓ P36888 2/20 0.37
PIK3CA P42336 6/20 0.38
NAAA Q02083 1/20 0.36
PRKCZ Q05513 1/20 0.36
CHRNA7 P36544 2/20 0.36
ATR Q13535 2/20 0.36
MTOR P42345 2/20 0.36
ATM Q13315 1/20 0.36
PIK3CG P48736 1/20 0.36
CYP2D6 P10635 1/20 0.35
PARP10 Q53GL7 1/20 0.35
PARP11 Q9NR21 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL744535 0.90 CHRNA7 (0.41) PIK3CDNAAACHRNA7
SCHEMBL747739 0.89 PIK3CD (0.38) PIK3CDPIK3CAFLT3CHRNA7ATR
SCHEMBL746345 0.88 PRKCZ (0.43) PIK3CDPIK3CAPRKCZATRMTOR
SCHEMBL743794 0.79 CHRNA7 (0.42) PIK3CDCHRNA7CYP2D6
SCHEMBL744608 0.78 CHRNA7 (0.42) PIK3CDNAAACHRNA7MTORCYP2D6
SCHEMBL747151 0.78 CYP2D6 (0.44) NAAACYP2D6
SCHEMBL747150 0.78 CYP2D6 (0.44) NAAACYP2D6
SCHEMBL746275 0.78 CHRNA7 (0.42) PIK3CDCHRNA7CYP2D6
SCHEMBL2484827 0.77 CHRNA7 (0.49) CHRNA7
SCHEMBL744341 0.77 CHRNA7 (0.49) CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2431368-B1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBVIE BAHAMAS LTD (BS) 2014-08-27 EP disclosed
EP-2431368-A1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives Abbott Laboratories (US) 2012-03-21 EP disclosed
EP-2018380-B1 Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LAB (US) 2011-10-19 EP disclosed
US-7872017-B2 Fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LABORATORIES (US) 2011-01-18 US disclosed
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives ABBOTT LABORATORIES (US) 2010-12-02 US disclosed
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES ABBVIE INC. 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES MALT1, BMP2, ALKBH2 PIK3CD 543/4885FLT3 670/4885PIK3CA 588/4885
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives MALT1, BMP2, ALKBH2 PIK3CD 543/4885FLT3 670/4885PIK3CA 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.